These results suggested that PTPRD/PTPRT mutation was a potential positive predictor for clinical benefit of anti-PD-(L)1 therapy in NSCLC instead of a prognosis factor for NSCLC. The gene discussed is PTPRT; the disease is non-small cell lung carcinoma.